Can atomoxetine (Strattera) cause epistaxis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Strattera Cause Bloody Nose?

No, atomoxetine (Strattera) does not commonly cause epistaxis (nosebleeds), and there is no established causal relationship between this medication and nosebleeds based on available evidence.

Evidence from FDA Drug Label

The FDA prescribing information for Strattera does not list epistaxis as a recognized adverse effect 1. The documented side effects include:

  • Sympathetic nervous system activation: tachycardia, blood pressure elevation, mydriasis, dry mouth
  • Common adverse events: gastrointestinal symptoms, somnolence, dizziness, tremor
  • Postmarketing reports: anxiety (but not epistaxis)

A comprehensive safety review of atomoxetine covering over a decade of research in children and adolescents examined seven major safety topics—suicidality, aggression/hostility, psychosis/mania, seizures, hepatic effects, cardiovascular effects, and growth/development—but epistaxis was not identified as a safety concern 2.

Clinical Context

The epistaxis guidelines extensively discuss risk factors for nosebleeds, including 3, 4:

  • Anticoagulant medications (warfarin, DOACs, heparin)
  • Antiplatelet agents (aspirin, clopidogrel)
  • Hypertension (though causal relationship unclear)
  • Inherited bleeding disorders (von Willebrand disease, hemophilia)
  • Hereditary hemorrhagic telangiectasia

Atomoxetine is not mentioned among medications associated with epistaxis risk in these comprehensive guidelines.

Practical Recommendation

If a patient on Strattera develops nosebleeds:

  • Do not attribute it to atomoxetine without investigating other causes
  • Evaluate for common epistaxis risk factors: digital trauma (especially in children), nasal dryness, environmental factors, concurrent anticoagulant use, hypertension, or bleeding disorders
  • Consider that 60% of the general population experiences at least one nosebleed, with 3 out of 4 children having at least one episode 3
  • Manage the epistaxis using standard first-line treatments: direct nasal compression, topical vasoconstrictors, cautery, or packing as indicated 3

The temporal association between starting Strattera and developing epistaxis is likely coincidental rather than causal, particularly given the high baseline prevalence of nosebleeds in the general population and the absence of this adverse effect in extensive safety monitoring.

References

Guideline

clinical practice guideline: nosebleed (epistaxis).

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2020

Guideline

clinical practice guideline: nosebleed (epistaxis) executive summary.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.